Nearly one out of four dogs will develop cancer in their lifetime and 20 per cent of those will be lymphoma cases.
A team of researchers from the University of Leicester has helped Avacta Animal Health Ltd to develop a new user-friendly electronic system for diagnosing lymphoma in dogs in the early stages, and for remission monitoring.
Marketed as cLBT (canine lymphoma blood test), this is the first test of its kind to track the remission monitoring status of a dog after undergoing chemotherapy.
Led by Professor Alexander Gorban from the University’s Department of Mathematics, the University team together with experts from Avacta elaborated technology for differential diagnosis of canine lymphoma and for remission monitoring.
This technology is based on the cLBT, which detects the levels of two biomarkers, the acute phase proteins C-Reactive Protein and Haptoglobin.
The paper ‘Computational diagnosis and risk evaluation for canine Lymphoma’ by E.M. Mirkes, I. Alexandrakis, K. Slater, R. Tuli and A.N. Gorban has been published in the academic journal Computers for Biology and Medicine and is available at the following location: http://dx.doi.org/10.1016/j.compbiomed.2014.08.006